Latest Capital Raises News

Keybridge Capital has posted a $6.14 million loss for the half-year ended 31 December 2024, driven by legacy governance issues and significant legal costs. A new board, appointed following court intervention, is now focused on stabilising the company and pursuing recovery actions.

Environmental Clean Technologies Limited reported a $2.58 million loss for the half-year ended December 2025, marking a strategic pivot with the acquisition of Terrajoule Pty Ltd and exclusive rights to innovative remediation technology.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

RooLife Group Ltd has reported a 144% surge in half-year revenue to $3.75 million, driven by strong growth in proprietary product sales, notably its RLG Coffee range in China. The company also reduced its net loss by 23%, reflecting operational improvements and strategic divestments.

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

I Synergy Group Limited reported a 15.63% drop in revenue to AUD 0.81 million for FY2025, alongside a 21.5% increase in net loss to AUD 0.34 million, with auditors flagging going concern uncertainties.

CONNEQT Health reported a 40% revenue increase to $2.28 million for the half-year ending December 2025, driven by strong sales of its CONNEQT Pulse device and early subscription uptake. Despite narrowing its net loss by 14%, the company continues to navigate operational restructuring and funding challenges as it pivots towards a recurring revenue model.

Skin Elements Limited reported a $4.01 million loss for the half-year ending December 2025, alongside a 41% revenue drop, while securing $2.5 million in fresh capital to advance its proprietary SE Formula biotechnology products.

Burgundy Diamond Mines reported a net loss of $86.8 million for 2025, reflecting operational challenges including the suspension of Point Lake mining due to adverse tariffs. The company secured $83.4 million in Canadian tariff relief financing to bolster liquidity and restructured its debt amid ongoing market uncertainties.

PainChek Limited reported a half-year loss of AUD 4.7 million but achieved a major regulatory milestone with FDA clearance for its Adult App, unlocking significant US market opportunities. The company also completed a share consolidation and raised capital to support growth.

DigitalX Limited reported a narrower half-year loss and increased revenues, underpinned by a strategic pivot to a Bitcoin-first treasury model and operational cost discipline.

NoviqTech Limited reported a widening loss of $2.83 million for 2025, alongside a severe drop in cash reserves and a looming going concern uncertainty flagged in its upcoming audit.